Rosuvastatin-d6 (sodium salt) |
| カタログ番号GC48060 |
ロスバスタチンの定量化のための内部標準
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2070009-41-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Rosuvastatin-d6 is intended for use as an internal standard for the quantification of rosuvastatin by GC- or LC-MS. Rosuvastatin is an HMG-CoA reductase inhibitor (IC50 = 5 nM).1,2 It is a fully-synthetic inhibitor that is designed to maximize the points of contact with, and inhibition of, HMG-CoA reductase.1 Formulations containing rosuvastatin reduce low-density lipoprotein and C-reactive protein and increase high-density lipoprotein in humans.3,4
1.Istvan, E.S., and Deisenhofer, J.Structural mechanism for statin inhibition of HMG-CoA reductaseScience292(5519)1160-1164(2001) 2.Tobert, J.A.Lovastatin and beyond: The history of the HMG-CoA reductase inhibitorsNat. Rev. Drug Discov.2(7)517-526(2003) 3.Asztalos, B.F., Maulf, F.L., Dallal, G.E., et al.Comparison of the effects of high doses of Rosuvastatin versus Atorvastatin on the subpopulations of high-density lipoproteinsAm. J. Cardiol.99(5)681-685(2007) 4.Rubba, P., Marotta, G., and Gentile, M.Efficacy and safety of rosuvastatin in the management of dyslipidemiaVasc. Health Risk Manag.5(1)343-352(2009)
Average Rating: 5 (Based on Reviews and 31 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *